Evonik, Phathom Pharma Enter Long-Term Supply Pact

Evonik has entered into a long-term supply agreement with Phathom Pharmaceuticals, under which Evonik will produce large-scale volumes of vonoprazan at its FDA-inspected manufacturing sites in Tippecanoe, IN, and Dossenheim, Germany.

 

“The manufacture of vonoprazan requires multi-step syntheses involving complex chemistries. We are delighted to be able to bring the right mix of technologies and assets to this collaboration,” said Thomas Riermeier, head of the Health Care business line at Evonik. “We provide customer-focused CDMO services in combination with excellent quality, enabling our trusted partner Phathom to fight gastrointestinal disorders worldwide.”
 

Evonik’s Health Care business is part of the life science division Nutrition & Care and represents a key growth business for Evonik. The agreement with Phathom builds on the company’s track record of delivering complex APIs to meet the clinical and commercial supply needs of biotech and large pharma customers around the world.   
 

“We are excited to partner with Evonik to help us bring novel, first-in-class treatment options to patients suffering with gastrointestinal disorders,” said Jay Buchanan, Vice President of Manufacturing and Supply Chain at Phathom Pharmaceuticals. “We value Evonik’s commitment to quality and expertise with API production and believe our partnership brings us closer to delivering on our mission to improve the lives of patients with gastrointestinal disorders.”
 

To address the specific needs of large or complex projects, Evonik has established a broad portfolio of technologies which can be combined to support multi-step API and HPAPI synthesis. These technologies include catalytic and biocatalytic reactions, large-scale cryogenic chemistry, continuous processing, fermentation, PEGs and mPEGs, catalysts, and polymer APIs. Evonik’s expertise in heterogeneous catalysis, in particular, was fundamental to achieving high efficiency and purity of the API used in vonoprazan.